| Autor: |
Akar, Emre, Baytekin, Halil F, Deniz, Hatice, Tural, Deniz |
| Předmět: |
|
| Zdroj: |
Journal of Oncology Pharmacy Practice; Jun2020, Vol. 26 Issue 4, p1022-1024, 3p, 1 Black and White Photograph |
| Abstrakt: |
Introduction: Immunotherapy with checkpoint inhibitors gains a major role in bladder cancer. Because of the treatment's immune modulatory effects, patients may develop hepatitis. Hepatitis B was an exclusion criterion in clinical trials that investigated nivolumab. Therefore, its effects and risk of hepatitis B reactivation in nivolumab are not clinically investigated in renal cell carcinoma patients with hepatitis B. Case report: In this case report, we presented a metastatic renal cell carcinoma patient who was treated with anti-viral treatment for hepatitis reactivation caused by previous sunitinib therapy. After progression, nivolumab was commenced and the patient was closely monitored with hepatic function tests. Management and outcome: Nivolumab was well tolerated and no treatment-related adverse effect occurred. Hepatitis or viral hepatitis reactivation was not detected. Discussion: This case supports the safety of nivolumab in patients with renal cell carcinoma and viral hepatitis. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
